mRNA Cancer Medicines for Every Patient
Teaching the immune system to find cancer and fight it.
Cancer hides from the immune system. ImmunoScript makes mRNA-based immunotherapies that carry two kinds of instructions at once:
Cytokines
Messengers that call immune cells into the tumor.
Tumor antigens
Markers that show immune cells what to attack.
Lasting
Train the body's own defenses for durable control.
Off the shelf
Made in advance. No custom batch, no waiting.
For every patient
One product, made at scale, within reach of many.
Why now
The era of mRNA cancer medicine has begun.
What's missing is one ready for every patient.
Proven
mRNA works at global scale
mRNA medicines can be designed quickly and made for millions.
Working
Personalized mRNA is fighting cancer
Custom-made mRNA treatments are helping patients in clinical trials. But each one is built for a single person, and that takes weeks.
Missing
An effective off-the-shelf immunotherapy
One ready-made mRNA therapy that works for many patients. That is the gap ImmunoScript is built to fill.
How it works
Two barriers. One therapy.
Tumors block immune cells at two steps: getting in and recognizing the cancer. Our lead therapy, IS-001, unlocks both.
Today: immune cells wait outside the tumor's wall.
Pipeline
Starting with pancreatic cancer.
Built to expand to other solid tumors.
IS-001 is our lead therapy targeting pancreatic cancer.
| Program | DiscoveryPreclinicalIND-enablingPhase 1 |
|---|---|
| IS-001Lead indication: pancreatic cancerA multiplexed mRNA therapy combining 5 cytokines and 3 tumor antigens. | |
| IS-002Lead indication: solid tumors (undisclosed) |
Results
What IS-001 achieved in preclinical studies.
Tested in aggressive mouse models of pancreatic cancer.
50%
Tumors disappeared
Half of treated tumors cleared completely.
1 year
Cancer stayed away
Tumors stayed away for a year, long after treatment stopped.
Lasting
Immune memory
The immune system learned to recognize the cancer and kept watch, so tumors did not return.
Team
Founded by the scientists behind the science.
Marcus Ruscetti, PhD
Co-Founder & Chief Scientific Advisor
Associate Professor, UMass Chan Medical School.
LinkedInNews
Follow our progress.
August 2026 · UMass Chan Medical School
UMass Chan scientists develop an mRNA immunotherapy that clears pancreatic tumors in mice
Read the article May 2026 · UMass Chan Medical SchoolCo-founder Marcus Ruscetti receives the 2026 Pershing Square Sohn Cancer Prize
Read the article October 2024 · Let's Win Pancreatic CancerCo-founder Chaitanya Parikh featured among the next generation of pancreatic cancer researchers
Read the articleOur research is making headlines around the world.
Publications
Peer-reviewed science.
2026
Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer
Read in Nature CommunicationsInvestors & partners
Let's talk about IS-001.
If you're interested in investing in or partnering on the next generation of cancer immunotherapy, send us a note. We read every message and reply personally.
We are also in early discussions to identify potential clinical trial sites. If you're a physician interested in IS-001, we'd be glad to hear from you.
Careers
We're always looking for exceptional people.
Across science, regulatory and business development. If you want to help build the next generation of cancer medicines, we'd love to hear from you.
Get in touch